Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial-Reference-Cited by-同舟云学术

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Published:2022-09 Issue:3 Volume:77 Page:607-618
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Alkhouri Naim,Herring Robert,Kabler Heidi,Kayali Zeid,Hassanein Tarek,Kohli Anita,Huss Ryan S.,Zhu Yanni,Billin Andrew N.,Damgaard Lars Holm,Buchholtz Kristine,Kjær Mette Skalshøi,Balendran Clare,Myers Robert P.,Loomba Rohit,Noureddin Mazen

Funder

Gilead Sciences

Novo Nordisk

Publisher

Elsevier BV

Subject

Hepatology

Reference30 articles.

1. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2018

2. MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis;Loomba;Hepatology,2021

3. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances;Noureddin;Am J Gastroenterol,2018

4. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up;Ekstedt;Hepatology,2015

5. Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease;Golabi;Hepatol Commun,2019

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

2. Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non‐Japanese Participants;The Journal of Clinical Pharmacology;2024-08-30

3. Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals;Current Obesity Reports;2024-08-07

4. Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies;Chinese Journal of Natural Medicines;2024-08

5. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?;Metabolism;2024-08